SlideShare a Scribd company logo
1 of 24
Siwanon Jirawatnotai, Ph.D.
Siriraj Laboratory of Systems Pharmacology,
Dept of Pharmacology, Siriraj Medical School
A Direct Role of Cyclin D1 in DNA Repair
Cyclin D1 is a cell cycle protein that drives mammalian cell division
gallus.reactome.org
A function of cyclin D1 in DNA repair uncovered by proteomic screenings
TAP Mass-spec
MCF-7,
ZR-75-1
UMSCC-2
GRANTA
519
HT29
Jirawatnotai, Nature 2011
Cyclin D1 is required for cell survival after DNA damage
0 h 16 h
sicont
siD1-B 0
20
40
60
80
Percentofcells
Tail length (pixels)
sicont
siD1-B
0
20
40
60
80
Percentofcells
Tail length (pixels)
***
*
***
0 h 16 h
Pierce A .,et al. 1999
0
20
40
60
80
100
120
Percent
***
0
20
40
60
80
100
120
Percent
***
Interaction between cyclin D1 and RAD51 facilitates efficient homologous recombination
Valerie et al., 2003
Oncogene
Cyclin D1 directly interacts with RAD51
SP49
Z138C
Granta 519
H2009
ZR-75-1
HT-29
IP
RAD IgG WCL
WB: cyclin D1
MCF7
In vivo bindingIn vitro binding
N-terminus domain of cyclin D1 and C-terminus domain of RAD51 are require for the
interaction
***
Interaction between cyclin D1 and RAD51 facilitates RAD51 loading to damage foci
0
20
40
60
80
100
0-2 3-9 10-19
Percentofcells
Foci/nucleus
4 h
***
***
***
***
*
*
0
20
40
60
80
100
0-2 3-9 10-19
Percentofcells
Foci/nucleus
0 h
0
20
40
60
80
100
0-2 3-9 10-19
Percentofcells
Foci/nucleus
2 h
*
***
***
***
***
*
0
20
40
60
80
100
0-2 3-9 10-19
Percentofcells
Foci/nucleus
8 h sicont
siD1-A
siD1-C
***
***
***
***
**
**
0
20
40
60
80
100
0-2 3-9 10-19
Percentofcells
Foci/nucleus
6 h
***
***
***
***
***
***
sicont
siD1-A
siD1-C
DAPI RAD51 -H2AX Merge
sicont
siD1-A
siD1-C
+ DNA damage
Cyclin D1 localizes at damaged DNA
0
2
4
6
8
Foldenrichment
Before DNA break
After DNA break
0
2
4
6
8
Foldenrichment
siD1
0
5
10
15
20
25
IgG Cyclin
D1
E2F4
Foldenrichment
Before DNA break
After DNA break
0
5
10
15
20
25
Foldenrichment
siD1
Pierce A .,et al. 1999
Targeted ChIP
DAPI - H2AX cyclin D1 Merge
Immunofluorescence
Interaction between cyclin D1 and BRCA2
B2-1
B2-3
B2-4
B2-5
B2-6
B2-7
B2-8
B2-9
B2-2
GST
Cyclin D1 binding to BRCA2 in vitro
(GST-pull-down)
BRCA2+/-H2AX+
siD1-A
sicont
Esashi, et al. 2005
Input GST
RAD51 binding to BRCA2 in vitro
(GST-pull-down)
Esashi, et al. 2005
Cyclin A/CDK2 phosphorylation
of BRCA2
Nocodazole
D1
GST-B2-9
Roscovitin +---
-+--
++++
Cyclin A
GST-B2-9
RAD51
Cyclin D1
GST B2-9
pull-down
293 cells
Phospho
BRCA2 S3291 Kinase assay
Kinase
assay
Expression of cyclin D1 helps recruit RAD51 to C-terminus domain of BRCA2 by
preventing the inhibitory S3291 phosphorylation by cyclin A/CDK2
Cyclin D1 expression helps
recruiting RAD51 to C-ter of
BRCA2
Phospho BRCA2 S3291
BRCA2
Cyclin D1
Cyclin B1
Cyclin A2
RAD51
CDK4
b-Actin
Async. G2/M (nocodazole)
- D1 Ro - D1 Ro
Cyclin B1 long exp
293 cells
Cyclin D1 expression prevents
B2-9 phosphorylation by CDK2
Lysate +++-
G2/M
-
Phospho BRCA2 S3291
Cyclin D1
Cyclin A2
CDK4
Cyclin B1
RAD51
HeLa cells
Expression of cyclin D1 helps recruit RAD51 to C-terminus domain of BRCA2 by
preventing the inhibitory S3291 phosphorylation by cyclin A/CDK2
Depletion of cyclin D1 by siRNA
increases S3291 phosphorylation
IP: B2-9
G2
IR (5 Gy) - + - +
Cyclin A2
Cyclin D1
BRCA2S3291
Asynchronous
GST B2-9
Cyclin D1 is recruited to C-terminus of BRCA2 upon DNA damage
WB
In vitro Competition assay
rHA-Cyclin D1
GST-BRCA2 C-Ter (B2-9) - + + + + + - + + + + +
rCyclin - - - -
+ + + + + + + + + + + +
DA
WB: HA
GST
Cyclin D1 controls phosphorylation of C-terminus BRCA2 by competing
with cyclin A for BRCA2 binding
Cyclin D1 cooperates with DNA damage to inhibit BRCA2
phosphorylation at Ser3291
Nocodazole - + - + - + - + - +
IR - - - - - - + + + +
D1 - - - - + + - - + +
Ros - - + + - - - - - -
1 2 3 4 5 6 7 8 9 10
S3291 Ph
cyclin D1
BRCA2
CDK4
actin
IB:
γH2AX
cyclin D1
IB:
GST
GST pulldown
0.5 1 2 4 6
Hour after IR
actin
IB:
S3291 Ph
BRCA2
cdc25a
NoIR
aa 20-90 of cyclin D1 is required for BRCA2-C-terminal binding
full-length
20-295
91-295
full-length
20-295
91-295
B2-5 B2-9 inp
IP
WB: Cyclin D1
full-length
WB:GST
B2-9 binding domain of cyclin D1 (aa 20-91) is required
to prevent CDK2/Cyclin A2 phosphorylation on B2-9
D1 1-295 1-90
IB:
GST
cyclin D1
B2-9 kinase assay
cyclin A-CDK2
0
20
40
60
80
100
120
0 nM 10 nM 20 nM 40 nM
Relativephosphorylationlevel
Concentration of recombinant cyclin D1
D1
del.91-
295
cyclin D1
Δ1-90
BSAB
S
A
BSA BSA
Cyclin box domain of cyclin D1 is required for RAD51 and BRCA2 binding
Cyclin box
Shot exp.
Long exp.
Shot exp.
Long exp.
Shot exp.
Long exp.
GST-B2-5
GST-B2-9
GST-pRb
GST-B2-9
GST-pRb
GST-B2-5
WB: GST
Cyclin D1 that is in complex with CDK4 does not compete with CDK2/cyclin A
Shot exp.
Long exp.
Kinase
assay
CDK4/Cyclin D1 CDK2/Cyclin A2
CDK2/Cyclin A2 CDK4/Cyclin D1
GST-B2-9
GST-Cyclin D1
GST-Cyclin A
WB: GST
1
10
100
0 Gy 2 Gy 4 Gy 6 GyPercentsurvival
0 µM
1 µM
3 µM
Cyclin D1 depletion hypersensitizes Rb-negative cancers to IR treatment
Jirawatnotai, Nature 2011
Cyclin D1 promotes RAD51 localization on damage
DNA, and HR
Jirawatnotai, Oncogene, in press
No DNA
damage
Severe DNA damage
Jirawatnotai, Cancer Research, 2012
Thanks
• Chonvara Chalermrujinanant
• Gunya Sittithumcharee
• Peter Sicinski, DFCI
– Wojtek Michowski
– Lisa Becks
• Fumiko Esashi (University of Oxford)
• David Livingston lab, DFCI
– Yiduo Hu
• Steve Gygi lab, HMS
– Joshua Elias
• John Quackenbush, CCCB, DFCI
– Yaoyu Wang
• Bing Xia (University of Medicine and Dentistry
• of New Jersey)

More Related Content

What's hot

"NF-kB " Pathway: Nuclear Factor Kappa Beta
"NF-kB " Pathway: Nuclear Factor Kappa Beta "NF-kB " Pathway: Nuclear Factor Kappa Beta
"NF-kB " Pathway: Nuclear Factor Kappa Beta idrish123
 
Clam DEG
Clam DEGClam DEG
Clam DEGsr320
 
Adrenoleucodistrofía, seminario biología molecular
Adrenoleucodistrofía, seminario biología molecular Adrenoleucodistrofía, seminario biología molecular
Adrenoleucodistrofía, seminario biología molecular David Herrera Correa
 
Apc tcell stimulation animation
Apc tcell stimulation animationApc tcell stimulation animation
Apc tcell stimulation animationGinnie Hench
 

What's hot (7)

apoptosis
apoptosisapoptosis
apoptosis
 
An RNA reset button
An RNA reset buttonAn RNA reset button
An RNA reset button
 
"NF-kB " Pathway: Nuclear Factor Kappa Beta
"NF-kB " Pathway: Nuclear Factor Kappa Beta "NF-kB " Pathway: Nuclear Factor Kappa Beta
"NF-kB " Pathway: Nuclear Factor Kappa Beta
 
Clam DEG
Clam DEGClam DEG
Clam DEG
 
Adrenoleucodistrofía, seminario biología molecular
Adrenoleucodistrofía, seminario biología molecular Adrenoleucodistrofía, seminario biología molecular
Adrenoleucodistrofía, seminario biología molecular
 
Gabe%27s poster II
Gabe%27s poster IIGabe%27s poster II
Gabe%27s poster II
 
Apc tcell stimulation animation
Apc tcell stimulation animationApc tcell stimulation animation
Apc tcell stimulation animation
 

Viewers also liked

Innovative clinical trial designs
Innovative clinical trial designs Innovative clinical trial designs
Innovative clinical trial designs Emad Shash
 
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Emad Shash
 
ABCs of Radiation Therapy for Patients, Family and Friends
ABCs of Radiation Therapy for Patients, Family and FriendsABCs of Radiation Therapy for Patients, Family and Friends
ABCs of Radiation Therapy for Patients, Family and FriendsDana-Farber Cancer Institute
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancerspa718
 
How is Radiation Therapy Used to Help Lung Cancer Patients?
How is Radiation Therapy Used to Help Lung Cancer Patients?How is Radiation Therapy Used to Help Lung Cancer Patients?
How is Radiation Therapy Used to Help Lung Cancer Patients?Dana-Farber Cancer Institute
 
Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Emad Shash
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancerfondas vakalis
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancerspa718
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancerspa718
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery spa718
 
Introduction to the world of oncology
Introduction to the world of oncologyIntroduction to the world of oncology
Introduction to the world of oncologyEmad Shash
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancerspa718
 
First Line Therapy in EGFR Mutant Advanced/Metastatic NSCLC
First Line Therapy in EGFR Mutant Advanced/Metastatic NSCLCFirst Line Therapy in EGFR Mutant Advanced/Metastatic NSCLC
First Line Therapy in EGFR Mutant Advanced/Metastatic NSCLCEmad Shash
 
Egypt cancer epidemiology
Egypt cancer epidemiologyEgypt cancer epidemiology
Egypt cancer epidemiologyEmad Shash
 

Viewers also liked (16)

Innovative clinical trial designs
Innovative clinical trial designs Innovative clinical trial designs
Innovative clinical trial designs
 
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
 
What You Should Know about Radiation Therapy
What You Should Know about Radiation TherapyWhat You Should Know about Radiation Therapy
What You Should Know about Radiation Therapy
 
ABCs of Radiation Therapy for Patients, Family and Friends
ABCs of Radiation Therapy for Patients, Family and FriendsABCs of Radiation Therapy for Patients, Family and Friends
ABCs of Radiation Therapy for Patients, Family and Friends
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancer
 
How is Radiation Therapy Used to Help Lung Cancer Patients?
How is Radiation Therapy Used to Help Lung Cancer Patients?How is Radiation Therapy Used to Help Lung Cancer Patients?
How is Radiation Therapy Used to Help Lung Cancer Patients?
 
Radiation for Lung Cancer
Radiation for Lung CancerRadiation for Lung Cancer
Radiation for Lung Cancer
 
Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancer
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancer
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancer
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery
 
Introduction to the world of oncology
Introduction to the world of oncologyIntroduction to the world of oncology
Introduction to the world of oncology
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancer
 
First Line Therapy in EGFR Mutant Advanced/Metastatic NSCLC
First Line Therapy in EGFR Mutant Advanced/Metastatic NSCLCFirst Line Therapy in EGFR Mutant Advanced/Metastatic NSCLC
First Line Therapy in EGFR Mutant Advanced/Metastatic NSCLC
 
Egypt cancer epidemiology
Egypt cancer epidemiologyEgypt cancer epidemiology
Egypt cancer epidemiology
 

More from spa718

Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerspa718
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomaspa718
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancerspa718
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancerspa718
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancerspa718
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancerspa718
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancerspa718
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015spa718
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancerspa718
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHDspa718
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myelomaspa718
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapyspa718
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapyspa718
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Updatespa718
 
Allogeneic HSCT in Elderly
Allogeneic HSCT in ElderlyAllogeneic HSCT in Elderly
Allogeneic HSCT in Elderlyspa718
 
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's LymphomaAllogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's Lymphomaspa718
 
Hodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment UpdateHodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment Updatespa718
 
Upfront AutoSCT in High Risk NHL
Upfront AutoSCT in High Risk NHLUpfront AutoSCT in High Risk NHL
Upfront AutoSCT in High Risk NHLspa718
 
Lymphoma: Treatment Updates
Lymphoma: Treatment UpdatesLymphoma: Treatment Updates
Lymphoma: Treatment Updatesspa718
 
Dengue Hemorrhagic Fever
Dengue Hemorrhagic FeverDengue Hemorrhagic Fever
Dengue Hemorrhagic Feverspa718
 

More from spa718 (20)

Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancer
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancer
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancer
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancer
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancer
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancer
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHD
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myeloma
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapy
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapy
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Update
 
Allogeneic HSCT in Elderly
Allogeneic HSCT in ElderlyAllogeneic HSCT in Elderly
Allogeneic HSCT in Elderly
 
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's LymphomaAllogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
 
Hodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment UpdateHodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment Update
 
Upfront AutoSCT in High Risk NHL
Upfront AutoSCT in High Risk NHLUpfront AutoSCT in High Risk NHL
Upfront AutoSCT in High Risk NHL
 
Lymphoma: Treatment Updates
Lymphoma: Treatment UpdatesLymphoma: Treatment Updates
Lymphoma: Treatment Updates
 
Dengue Hemorrhagic Fever
Dengue Hemorrhagic FeverDengue Hemorrhagic Fever
Dengue Hemorrhagic Fever
 

1600 1620 siwanon jirawatnotai

  • 1. Siwanon Jirawatnotai, Ph.D. Siriraj Laboratory of Systems Pharmacology, Dept of Pharmacology, Siriraj Medical School A Direct Role of Cyclin D1 in DNA Repair
  • 2. Cyclin D1 is a cell cycle protein that drives mammalian cell division gallus.reactome.org
  • 3. A function of cyclin D1 in DNA repair uncovered by proteomic screenings TAP Mass-spec MCF-7, ZR-75-1 UMSCC-2 GRANTA 519 HT29 Jirawatnotai, Nature 2011
  • 4. Cyclin D1 is required for cell survival after DNA damage 0 h 16 h sicont siD1-B 0 20 40 60 80 Percentofcells Tail length (pixels) sicont siD1-B 0 20 40 60 80 Percentofcells Tail length (pixels) *** * *** 0 h 16 h
  • 5. Pierce A .,et al. 1999 0 20 40 60 80 100 120 Percent *** 0 20 40 60 80 100 120 Percent *** Interaction between cyclin D1 and RAD51 facilitates efficient homologous recombination Valerie et al., 2003 Oncogene
  • 6. Cyclin D1 directly interacts with RAD51 SP49 Z138C Granta 519 H2009 ZR-75-1 HT-29 IP RAD IgG WCL WB: cyclin D1 MCF7 In vivo bindingIn vitro binding
  • 7. N-terminus domain of cyclin D1 and C-terminus domain of RAD51 are require for the interaction ***
  • 8. Interaction between cyclin D1 and RAD51 facilitates RAD51 loading to damage foci 0 20 40 60 80 100 0-2 3-9 10-19 Percentofcells Foci/nucleus 4 h *** *** *** *** * * 0 20 40 60 80 100 0-2 3-9 10-19 Percentofcells Foci/nucleus 0 h 0 20 40 60 80 100 0-2 3-9 10-19 Percentofcells Foci/nucleus 2 h * *** *** *** *** * 0 20 40 60 80 100 0-2 3-9 10-19 Percentofcells Foci/nucleus 8 h sicont siD1-A siD1-C *** *** *** *** ** ** 0 20 40 60 80 100 0-2 3-9 10-19 Percentofcells Foci/nucleus 6 h *** *** *** *** *** *** sicont siD1-A siD1-C DAPI RAD51 -H2AX Merge sicont siD1-A siD1-C + DNA damage
  • 9. Cyclin D1 localizes at damaged DNA 0 2 4 6 8 Foldenrichment Before DNA break After DNA break 0 2 4 6 8 Foldenrichment siD1 0 5 10 15 20 25 IgG Cyclin D1 E2F4 Foldenrichment Before DNA break After DNA break 0 5 10 15 20 25 Foldenrichment siD1 Pierce A .,et al. 1999 Targeted ChIP DAPI - H2AX cyclin D1 Merge Immunofluorescence
  • 10. Interaction between cyclin D1 and BRCA2 B2-1 B2-3 B2-4 B2-5 B2-6 B2-7 B2-8 B2-9 B2-2 GST Cyclin D1 binding to BRCA2 in vitro (GST-pull-down) BRCA2+/-H2AX+ siD1-A sicont Esashi, et al. 2005 Input GST RAD51 binding to BRCA2 in vitro (GST-pull-down) Esashi, et al. 2005 Cyclin A/CDK2 phosphorylation of BRCA2
  • 11. Nocodazole D1 GST-B2-9 Roscovitin +--- -+-- ++++ Cyclin A GST-B2-9 RAD51 Cyclin D1 GST B2-9 pull-down 293 cells Phospho BRCA2 S3291 Kinase assay Kinase assay Expression of cyclin D1 helps recruit RAD51 to C-terminus domain of BRCA2 by preventing the inhibitory S3291 phosphorylation by cyclin A/CDK2 Cyclin D1 expression helps recruiting RAD51 to C-ter of BRCA2 Phospho BRCA2 S3291 BRCA2 Cyclin D1 Cyclin B1 Cyclin A2 RAD51 CDK4 b-Actin Async. G2/M (nocodazole) - D1 Ro - D1 Ro Cyclin B1 long exp 293 cells Cyclin D1 expression prevents B2-9 phosphorylation by CDK2 Lysate +++-
  • 12. G2/M - Phospho BRCA2 S3291 Cyclin D1 Cyclin A2 CDK4 Cyclin B1 RAD51 HeLa cells Expression of cyclin D1 helps recruit RAD51 to C-terminus domain of BRCA2 by preventing the inhibitory S3291 phosphorylation by cyclin A/CDK2 Depletion of cyclin D1 by siRNA increases S3291 phosphorylation
  • 13. IP: B2-9 G2 IR (5 Gy) - + - + Cyclin A2 Cyclin D1 BRCA2S3291 Asynchronous GST B2-9 Cyclin D1 is recruited to C-terminus of BRCA2 upon DNA damage WB
  • 14. In vitro Competition assay rHA-Cyclin D1 GST-BRCA2 C-Ter (B2-9) - + + + + + - + + + + + rCyclin - - - - + + + + + + + + + + + + DA WB: HA GST Cyclin D1 controls phosphorylation of C-terminus BRCA2 by competing with cyclin A for BRCA2 binding
  • 15. Cyclin D1 cooperates with DNA damage to inhibit BRCA2 phosphorylation at Ser3291 Nocodazole - + - + - + - + - + IR - - - - - - + + + + D1 - - - - + + - - + + Ros - - + + - - - - - - 1 2 3 4 5 6 7 8 9 10 S3291 Ph cyclin D1 BRCA2 CDK4 actin IB: γH2AX cyclin D1 IB: GST GST pulldown 0.5 1 2 4 6 Hour after IR actin IB: S3291 Ph BRCA2 cdc25a NoIR
  • 16. aa 20-90 of cyclin D1 is required for BRCA2-C-terminal binding full-length 20-295 91-295 full-length 20-295 91-295 B2-5 B2-9 inp IP WB: Cyclin D1 full-length WB:GST B2-9 binding domain of cyclin D1 (aa 20-91) is required to prevent CDK2/Cyclin A2 phosphorylation on B2-9 D1 1-295 1-90 IB: GST cyclin D1 B2-9 kinase assay cyclin A-CDK2 0 20 40 60 80 100 120 0 nM 10 nM 20 nM 40 nM Relativephosphorylationlevel Concentration of recombinant cyclin D1 D1 del.91- 295 cyclin D1 Δ1-90 BSAB S A BSA BSA
  • 17. Cyclin box domain of cyclin D1 is required for RAD51 and BRCA2 binding Cyclin box
  • 18. Shot exp. Long exp. Shot exp. Long exp. Shot exp. Long exp. GST-B2-5 GST-B2-9 GST-pRb GST-B2-9 GST-pRb GST-B2-5 WB: GST Cyclin D1 that is in complex with CDK4 does not compete with CDK2/cyclin A Shot exp. Long exp. Kinase assay CDK4/Cyclin D1 CDK2/Cyclin A2 CDK2/Cyclin A2 CDK4/Cyclin D1 GST-B2-9 GST-Cyclin D1 GST-Cyclin A WB: GST 1 10 100 0 Gy 2 Gy 4 Gy 6 GyPercentsurvival 0 µM 1 µM 3 µM
  • 19. Cyclin D1 depletion hypersensitizes Rb-negative cancers to IR treatment Jirawatnotai, Nature 2011
  • 20. Cyclin D1 promotes RAD51 localization on damage DNA, and HR Jirawatnotai, Oncogene, in press
  • 21. No DNA damage Severe DNA damage Jirawatnotai, Cancer Research, 2012
  • 22.
  • 23.
  • 24. Thanks • Chonvara Chalermrujinanant • Gunya Sittithumcharee • Peter Sicinski, DFCI – Wojtek Michowski – Lisa Becks • Fumiko Esashi (University of Oxford) • David Livingston lab, DFCI – Yiduo Hu • Steve Gygi lab, HMS – Joshua Elias • John Quackenbush, CCCB, DFCI – Yaoyu Wang • Bing Xia (University of Medicine and Dentistry • of New Jersey)